<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947440</url>
  </required_header>
  <id_info>
    <org_study_id>M11-056</org_study_id>
    <nct_id>NCT00947440</nct_id>
  </id_info>
  <brief_title>Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation</brief_title>
  <official_title>An Open-Label, Randomized, Crossover Study to Evaluate the Bioavailability of Two Candidate Tablet Formulations of ABT-072 With Reference to the Capsule Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioavailability, safety, tolerability and
      pharmacokinetics of two tablet formulations as compared to the capsule formulation suspended
      in liquid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-dose, three period, complete cross-over study to evaluate the relative
      bioavailability, pharmacokinetics, safety and tolerability of two candidate tablet
      formulations of ABT-072 when compared to that of the original capsule formulation suspended
      in liquid as a reference.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the relative bioavailability of two candidate tablet formulations of ABT-072 to that of the capsule formulation.</measure>
    <time_frame>4 days post each dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety and tolerability of two candidate tablet formulations of ABT-072 to that of the capsule formulation.</measure>
    <time_frame>Through 14 days post last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Tablet 1 vs. Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 2 x 50 mg tablets (Tablet 1) vs. 100 mg ABT-072 (contents of capsules) suspended in liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet 2 vs. Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 2 x 50 mg tablets (Tablet 2) vs. 100 mg ABT-072 (contents from capsules) suspended in liquid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-072</intervention_name>
    <description>See arm description for more information</description>
    <arm_group_label>Tablet 1 vs. Capsule</arm_group_label>
    <arm_group_label>Tablet 2 vs. Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overall healthy subjects, non-childbearing females included.

        Exclusion Criteria:

          -  Use of any medications (prescription and over-the-counter), vitamins, or herbal
             supplements within the 2-week period prior to the first dose of study drug
             administration or within 10 half-lives of the respective medication, whichever is
             longer.

          -  Pregnant or breast-feeding female.

          -  Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B
             surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV
             Ab).

          -  Positive screen for drugs of abuse, alcohol, or cotinine.

          -  Clinically significant cardiovascular, respiratory (except mild asthma), renal,
             gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical
             illness or psychiatric disorder.

          -  Use of tobacco or nicotine-containing products within the 6-month period preceding
             study drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 22384</name>
      <address>
        <city>Waukegan</city>
        <state>Illinois</state>
        <zip>60085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>July 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <last_update_submitted>October 19, 2010</last_update_submitted>
  <last_update_submitted_qc>October 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daniel Cohen, MD/Study Medical Director</name_title>
    <organization>Abbott Laboratories</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Bioavailability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

